<![CDATA[FDA Withdraws Adagrasib/Cetuximab Approval in KRAS G12C-Mutated CRC]]>
Regulatoryrejectedadagrasib/cetuximabNegative
AI Analysis
Summary
The FDA withdrew accelerated approval for Kura Oncology's adagrasib/cetuximab combination in KRAS G12C-mutated colorectal cancer after the KRYSTAL-10 trial failed to demonstrate survival improvement.
Clinical Trial Data
Primary Endpoint
Not Met
Outcome Details
FDA withdrew accelerated approval for adagrasib/cetuximab combination in KRAS G12C-mutated colorectal cancer following failure to improve survival in KRYSTAL-10 trial
Importance:9/10
Sentiment:
-1.00
FDA withdrawalaccelerated approvalKRAS G12Ccolorectal cancerKRYSTAL-10survival endpoint failed
Related Companies
Read the original article
Published by Cancer Network on September 8, 2026 9:00 PM